Abbvie Inc.

Abbott Laboratories Corporation

Nathan Josephsohn

Kristine E Frank

David J Calderwood

Michael M Friedman

Anna M Ericsson

Neil Wishart

Maria A Argiriadi

Biqin C Li

Lu Wang

Dawn M George

Eric R Goedken

Kent D Stewart

Kevin R Woller

Michael Morytko

Jeffrey W Voss

Grier A Wallace

Bryan A Fiamengo

Anil Vasudevan

Mikhail A Chafeev

Michael Z Hoemann

David Wayne Borhani

Eric C Breinlinger

Kelly Mullen

Heather M Davis

Gagandeep K Somal

Tatyana Dekhtyar

M-akhteruzzaman Molla

Iok Chan Ng

Artour Gomtsian

Barbara S Skinner

Mikhail Chafeev

Teresa Ng

M-Akhteruzz Molla

This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 

Substituted cyanoguanidines as oral anti-virals

The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.

Tricyclic compounds

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

The invention provides a compound of Formula (Ie), 

Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Imidazothiazoles and imidazoxazoles

Growing community of inventors

Boston, MA, United States of America

Nathan Josephsohn